Collegium Pharmaceutical, Inc. (COLL) Stock Analysis

Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks

Mon, October 26, 2026 at 11:42 PM UTC 2 min read

Collegium Pharmaceutical (NASDAQ: COLL) reported mixed Q2 earnings, with results that diverged from broader trends in the branded pharmaceuticals sector. While the company achieved notable revenue growth, it faced challenges in profit margins compared to its peers. This performance is significant for investors as it highlights Collegium's potential for growth amidst industry fluctuations, but also underscores the need for careful evaluation of its profitability moving forward.

Read full article →

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

Fri, October 16, 2026 at 12:55 PM UTC 2 min read

Collegium Pharmaceutical (COLL) has garnered attention as Wall Street analysts project a potential rally of 111.39% for the stock. This optimistic outlook is driven by the company's strong pipeline and recent positive developments in its pain management portfolio. For investors, this forecast highlights the potential for significant returns, making COLL an intriguing option in the pharmaceutical sector.

Read full article →